Relay Therapeutics, Inc. (RLAY) recently announced that it had achieved positive interim data from its ongoing phase 1 ReDiscover study, using its drug RLY-2608 + fulvestrant for the treatment of ...
Editorial Note: Talk Android may contain affiliate links on some articles. If you make a purchase through these links, we will earn a commission at no extra cost to you. Learn more. Fast on the heels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results